Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers

OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) when no more than two prior cytotoxic regimens have been used; due to concerns...

Full description

Saved in:
Bibliographic Details
Published in:J Gynecol Oncol
Main Authors: Martin, Jovana Y., Urban, Renata R., Liao, John B., Goff, Barbara A.
Format: Artigo
Language:Inglês
Published: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944014/
https://ncbi.nlm.nih.gov/pubmed/27329195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2016.27.e47
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items